Salix Pharmaceuticals

Salix Pharmaceuticals Newswire (Page 9)

Comprehensive Real-Time News Feed for Salix Pharmaceuticals. (Page 9)

Results 161 - 180 of 1,260 in Salix Pharmaceuticals

  1. Market Chatter- Corporate finance press digest - Sept 17Read the original story

    Sep 16, 2014 | Reuters

    * Some of the top 20 investors at Salix Pharmaceuticals Ltd are threatening to vote down a proposed deal to buy a unit of Cosmo Pharmaceuticals SpA, and are pressing Salix to consider selling itself instead, people familiar with the matter said on ...

    Comment?

  2. Us Stocks-Biotechs bounce after three-day slideRead the original story

    Sep 16, 2014 | Reuters

    ... falling nearly 4 percent from its most recent record high on August 29 before Tuesday's gains. Salix Pharmaceuticals shares, up 4 percent to $154.73, were among the bright spots in the group after the company said late Monday its treatment for ...

    Comment?

  3. Valeant, Allergan Settle Suit, Allow Shareholder VoteRead the original story w/Photo

    Sep 16, 2014 | Investor's Business Daily

    But while the meeting go-ahead makes a merger likelier, BMO Capital Markets analyst David Maris reported after a visit with "Allergan mentioned that it would not be surprised if some of the shareholders who are electing to participate in the special meeting will actually vote in favor of Allergan," Maris wrote in his research report Tuesday. "Based on our discussions with several holders, we believe that we have independently confirmed that there are holders participating in the meeting who state to us they intend to vote against Valeant's measure."

    Comment?

  4. Stocks Erase Modest Gains; Netflix Gaps Below 50-Day LineRead the original story w/Photo

    Sep 16, 2014 | Investor's Business Daily

    Stocks held on to modest gains about two hours into Tuesday's session, one day after the Nasdaq notched its third distribution day in five trading sessions. The S&P 500 gained 0.4%; the Dow Jones industrial average added 0.2% and the Nasdaq rose 0.1%.

    Comment?

  5. FDA approves AstraZeneca, Nektar constipation drugRead the original story

    Sep 16, 2014 | Reuters

    ... or Sucampo Pharmaceutical's stool softener Amitiza, Nektar said. Movantik will likely compete with Salix Pharmaceuticals Ltd and Progenics Pharmaceutical's subcutaneous injection Relistor - slated for an FDA decision this month for the same patient ...

    Comment?

  6. Salix receives tentative approval for ulcerative colitis drugRead the original story w/Photo

    Sep 16, 2014 | Business Journal

    Tentative approval from the U.S. Food and Drug Administration means Salix meets manufacturing quality and clinical safety and efficacy standards and will be granted final approval after the resolution of patent issues. Salix executives say they expect resolution of these patent issues early in the fourth quarter of 2014 and the launch of Uceris rectal foam during the first quarter of 2015.

    Comment?

  7. Salix Pharmaceuticals, Ltd. Release: UCERIS (budesonide) 2mg...Read the original story

    Sep 16, 2014 | BioSpace

    Salix Pharmaceuticals, Ltd. today announced that the FDA has granted tentative approval for UCERISA rectal foam for the induction of remission in patients with active mild-to-moderate distal ulcerative colitis extending up to 40cm from the anal verge. The foam is a rectally administered corticosteroid that overcomes treatment limitations associated with currently approved therapies which are often ineffective due to insufficient distribution of active drug to the distal colon.

    Comment?

  8. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Sep 15, 2014 | Business Wire

    ... of Remission of Mild-to-Moderate Distal Ulcerative Colitis Granted Tentative Approval by FDA )--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the FDA has granted tentative approval for UCERIS (budesonide) rectal foam for the ...

    Comment?

  9. Stock Market Today: Growth Stocks Get PunishedRead the original story w/Photo

    Sep 15, 2014 | Investor's Business Daily

    The Nasdaq slumped 1.1%, while the S&P 500 fell less than 0.1% and the Dow bucked the downdraft with a 0.3% gain. Volume ran higher on the Nasdaq but lower on the NYSE, according to preliminary data.

    Comment?

  10. UCERIS (budesonide) 2mg Rectal Foam for the Induction of Remission...Read the original story w/Photo

    Sep 15, 2014 | Investor's Business Daily

    Salix Pharmaceuticals, Ltd. today announced that the FDA has granted tentative approval for UCERISA rectal foam for the induction of remission in patients with active mild-to-moderate distal ulcerative colitis extending up to 40cm from the anal verge. The foam is a rectally administered corticosteroid that overcomes treatment limitations associated with currently approved therapies which are often ineffective due to insufficient distribution of active drug to the distal colon.

    Comment?

  11. Raleigh's Salix signs deal for drug sales in CanadaRead the original story w/Photo

    Sep 15, 2014 | Business Journal

    Raleigh's Salix Pharmaceuticals , Inc agreed to a deal in which Lupin Limited will sell certain Salix drugs in Canada. The deal includes immediate rights to distribute Zaxine for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older, and Relistor for the treatment of opioid-induced constipation in certain patients.

    Comment?

  12. UCERIS 2mg Rectal Foam For The Induction Of Remission Of...Read the original story w/Photo

    Sep 15, 2014 | Benzinga

    Salix Pharmaceuticals, Ltd. today announced that the FDA has granted tentative approval for UCERIS rectal foam for the induction of remission in patients with active mild-to-moderate distal ulcerative colitis extending up to 40cm from the anal verge. The foam is a rectally administered corticosteroid that overcomes treatment limitations associated with currently approved therapies which are often ineffective due to insufficient distribution of active drug to the distal colon.

    Comment?

  13. Court Report - September 2014 #4Read the original story w/Photo

    Sep 15, 2014 | JD Supra

    ... of general anesthesia and sedation in certain patient populations). View the Delaware complaint Salix Pharmaceuticals, LTD et al. v. Mylan Pharmaceuticals Inc. 1:14-cv-00152; filed September 8, 2014 in the Northern District of West Virginia ...

    Comment?

  14. Gilead, Jazz, Salix Among Top 6 IBD 50 DrugmakersRead the original story w/Photo

    Sep 12, 2014 | Investor's Business Daily

    Biotech and pharmaceutical companies are on the rise with life-saving promises, adding to hopes that their stocks will also be healthy investments. The industry was down Friday on general market weakness and concerns over growth stocks.

    Comment?

  15. Facebook, Other Leaders Waffle After Topping Buy PointsRead the original story w/Photo

    Sep 12, 2014 | Investor's Business Daily

    Several Sector Leaders are struggling after clearing buy points, reflecting sideways action in the overall market recently. Salix Pharmaceuticals soared past a 141.91 flat-base buy point Aug. 19 on reports that the drugmaker could be a takeover target for Allergan , which is trying to fend off a takeover bid from Valeant Pharmaceuticals .

    Comment?

  16. Lupin in pact for CanadaRead the original story w/Photo

    Sep 12, 2014 | The Telegraph

    Mumbai, Sept. 12: Lupin has entered into an agreement with US-based Salix Pharmaceuticals to market the latter's two products in Canada.

    Comment?

  17. The Best Pharma ETFRead the original story w/Photo

    Sep 12, 2014 | Seeking Alpha

    ... across its holdings. It has 34 holdings and equally weights them, with the largest holding currently Salix Pharmaceuticals (NASDAQ: SLXP ). It also has assets pretty evenly split across large, mid and small cap. This gives XPH the smallest average ...

    Comment?

  18. Credit Suisse Sees Downside In Shares Of Salix Pharmaceuticals, Ltd.Read the original story w/Photo

    Sep 12, 2014 | Benzinga

    Analysts at Credit Suisse initiated coverage on Salix Pharmaceuticals, Ltd. with an Underperform rating and $139 price target Friday. An acquisition by AGN is unlikely.

    Comment?

  19. BioDelivery Sciences International's (BDSI) CEO Mark Sirgo Presents...Read the original story w/Photo

    Sep 9, 2014 | Seeking Alpha

    Thanks everyone for joining the BDSI session. I am Chris Caponetti and I encourage you to please visit morganstanley.com/researchdisclosures for disclaimers.

    Comment?

  20. Synergy Pharmaceuticals Could Be A Diamond In The RoughRead the original story w/Photo

    Sep 8, 2014 | Seeking Alpha

    Synergy's lead drug plecanatide appears just as effective as Ironwood's Linzess, but with a notably better side effect profile. The market for prescription drugs to treat constipation appears underdeveloped today, but could be worth $3 billion by the end of the decade.

    Comment?